Deamidated Gliadin

Monoclonal antibody to deamidated Gliadin

100 µg 495 € available

Art. No. A160
Background info Tissue transglutaminase (TG2) catalyzes gliadin deamidation in the intestinal mucosa of celiac disease patients, resulting in deamidated gliadin peptides which are recognized by HLA receptors (DQ2/DQ8) of immune cells. Antibodies to deamidated gliadin have been proven to be specific for celiac disease – in contrast to gliadin antibodies. Detection of deamidated gliadin antibodies now is used in celiac disease diagnostics.
Host Mouse
Clone ZDG-01
Isotype IgG2a/k
Immunogen Deamidated gliadin-related peptide Lys57-Glu65-[α-gliadin (58-73)] (KLQPFPQPELPYPQPQ).
Specificity Recognizes Gliadin. Reacts with the deamidated gliadin peptide (KLQPFPQPELPYPQPQ).
Weakly cross-reacts (5%) with the non-deamidated gliadin peptide (KLQPFPQPQLPYPQPQ).
Appearance liquid, 100 μL with ~ 1 mg/mL
Description The antibody is supplied as a liquid in PBS, pH 7.4
Application Suitable for use in ELISA and Western Blot. Other applications not tested.
Working dilutions Optimal dilutions should be determined by the end user.
The following are guidelines only:
ELISA: 1 / 64,000
Western-Blot: 1 / 1,000
Storage Stable for short term at + 4 °C
For extended periods: store aliquots at – 20 °C
Reference(s) Skovbjerg et al., Biochim. Biophys. Acta. 2004, 1690, 220-30


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy